Park Yong Serk
Department of Biomedical Laboratory Science, Yonsei University, Wonju, Republic of Korea.
Biosci Rep. 2002 Apr;22(2):267-81. doi: 10.1023/a:1020190606757.
Tumor-specific targeting is a critical goal in the research area of liposomal drug delivery. Identification of the specific interactions between ligands and target tumor cells is a principle prerequisite in achieving this goal. Generally, tumor cells aberrantly express tumor-associated antigens that can be utilized as appropriate target molecules. Monoclonal antibodies against tumor-associated antigens have been successfully adopted for targeting to various types of cancer cells. The incorporation of humanized monoclonal antibodies or single chain human antibodies, instead of rodent antibodies into immunoliposomes has resulted in better clinical applicability. Tumor-specific ligands other than monoclonal antibodies have also been investigated as in vivo tumor-directing molecules. However, the number of pre-clinical studies of anticancer treatments using tumor-specific liposomal drugs reporting successful targeting and enhanced therapeutic efficacy has been limited. Further refinement of tumor-specific interactions and liposomal formulations will be necessary for the application of the tumor-specific liposomal drug strategy for anticancer chemotherapy or gene therapy.
肿瘤特异性靶向是脂质体药物递送研究领域的一个关键目标。识别配体与靶肿瘤细胞之间的特异性相互作用是实现这一目标的主要前提条件。一般来说，肿瘤细胞异常表达可作为合适靶分子的肿瘤相关抗原。针对肿瘤相关抗原的单克隆抗体已成功用于靶向各种类型的癌细胞。将人源化单克隆抗体或单链人抗体而非啮齿动物抗体掺入免疫脂质体中，已产生了更好的临床适用性。除单克隆抗体外，肿瘤特异性配体也已作为体内肿瘤导向分子进行了研究。然而，使用肿瘤特异性脂质体药物进行抗癌治疗的临床前研究中，报告成功靶向和增强治疗效果的数量有限。对于将肿瘤特异性脂质体药物策略应用于抗癌化疗或基因治疗而言，进一步优化肿瘤特异性相互作用和脂质体制剂将是必要的。
